Free Trial

Crinetics Pharmaceuticals Q2 2023 Earnings Report

Crinetics Pharmaceuticals logo
$53.60 +0.86 (+1.63%)
(As of 12/20/2024 05:16 PM ET)

Crinetics Pharmaceuticals EPS Results

Actual EPS
-$0.94
Consensus EPS
-$0.85
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Crinetics Pharmaceuticals Revenue Results

Actual Revenue
$0.99 million
Expected Revenue
$5.00 million
Beat/Miss
Missed by -$4.01 million
YoY Revenue Growth
N/A

Crinetics Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Most People Are Dead Wrong. (Ad)

Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Crinetics Pharmaceuticals Earnings Headlines

Most People Are Dead Wrong.
Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.
Crinetics Pharmaceuticals Strengthens Leadership with New Appointment
See More Crinetics Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Crinetics Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crinetics Pharmaceuticals and other key companies, straight to your email.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals (NASDAQ:CRNX), a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

View Crinetics Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings